Changes to Pharmaceutical Sales Regulations and Competition in Online Sales
First written in FY2016. 19 of 21 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2021: 1 of 8 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If regulations on pharmaceutical sales are further relaxed and entry by companies from other industries and competition with online sellers intensify, this could affect the operations of the Group's stores and other business activities.」
On the basis that online sales of over-the-counter pharmaceuticals have been permitted, the continued risks identified are further easing of sales regulations, entry by companies from other industries and intensified competition with online retailers. - FY2025RestatedAnnual report
「If regulations on pharmaceutical sales are further relaxed and entry by companies from other industries and competition with online sellers intensify, this could affect the operations of the Group's stores and other business activities.」
It continues to identify further deregulation, entry by companies from other industries and intensifying competition with online sellers as risks, following the lifting of the ban on online sales of over-the-counter drugs. - FY2024-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes to the existing business and other risks, including changes in pharmaceutical sales regulations and competition from online sellers. - FY2022RestatedAnnual report
「The Act Partially Amending the Pharmaceutical Affairs Act, which took effect on 12 June 2014, effectively lifted the ban on online sales of over-the-counter drugs. In addition, deregulation is being considered for the management, sale and provision of information on over-the-counter drugs by retail businesses using information and communications equipment. If regulations on pharmaceutical sales are further relaxed and entry by companies from other industries and competition with online sellers intensify, this could affect the operations of the Group's stores and other business activities.」
On the basis that online sales of over-the-counter pharmaceuticals have been permitted, the continued risks identified are further easing of sales regulations, entry by companies from other industries and intensified competition with online retailers. - FY2022-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2022-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2021RestatedAnnual report
「The Act Partially Amending the Pharmaceutical Affairs Act, which took effect on 12 June 2014, effectively lifted the ban on online sales of over-the-counter pharmaceuticals. In addition, the easing of regulations such as restrictions on the hours during which over-the-counter pharmaceuticals may be sold is under consideration. If pharmaceutical sales regulations are eased further in the future, leading to increased entry by companies from other industries and intensified competition with online retailers, this may affect the operations of the Group's stores and other business activities.」
On the basis that online sales of over-the-counter pharmaceuticals have been permitted, the continued risks identified are further easing of sales regulations, entry by companies from other industries and intensified competition with online retailers. - FY2021-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2021-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2020-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2020-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2020-Q1RestatedAnnual report
「During the three-month period ended June 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2019ReframedAnnual report
「The Act Partially Amending the Pharmaceutical Affairs Act (promulgated on 13 December 2013, effective from 12 June 2014) effectively lifted the ban on online sales of over-the-counter pharmaceuticals. If pharmaceutical sales regulations are eased further in the future, leading to increased entry by companies from other industries and intensified competition with online retailers, this may affect the operations of the Group's stores and other business activities.」
The description has shifted from the previous assumption-based wording, "if restrictions on online sales are eased," to identifying further regulatory easing and intensified competition as risks on the basis that online sales of over-the-counter pharmaceuticals have already effectively been permitted. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2019-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2019-Q1RestatedAnnual report
「During the three-month period ended June 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2018RestatedAnnual report
「If restrictions on the online sale of pharmaceuticals are eased, companies from other industries may enter the market and competition with online retailers may intensify. Accordingly, future amendments to such laws and regulations may affect the operations of the Group's stores and other business activities.」
The risk of increased competition with companies from other industries and online retailers resulting from the easing of restrictions on online pharmaceutical sales and amendments to laws and regulations continues to be identified. - FY2018-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2018-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes concerning changes in pharmaceutical sales regulations and competition in online sales. - FY2017RestatedAnnual report
「If restrictions on the online sale of pharmaceuticals are eased, companies from other industries may enter the market and competition with online retailers may intensify. Accordingly, future amendments to such laws and regulations may affect the operations of the Group's stores and other business activities.」
The risk of increased competition with companies from other industries and online retailers resulting from the easing of restrictions on online pharmaceutical sales and amendments to laws and regulations continues to be identified. - FY2016First statedAnnual report
「If restrictions on the online sale of pharmaceuticals are eased, companies from other industries may enter the market and competition with online retailers may intensify.」
It describes the possibility that amendments to the Pharmaceuticals and Medical Devices Act and other legislation, and the easing of restrictions on online sales, may affect store operations.